A medical technology developer, providing molecular diagnostic systems and medical devices for the management of diabetes and clinical diagnostics, PositiveID has announced that Receptors, its development partner headquartered in Minneapolis, Minnesota will showcase the recently developed synthetic sensing system at the 11th Annual Diabetes Technology Meeting being held at Burlingame’s Hyatt Regency San Francisco Airport, CA from 27 to 29 October, 2011.
The closed-cycle, synthetic sensing system was developed by Receptors for use in the implantable glucose sensor, which will be integrated into GlucoChip, a microchip developed by PositiveID for sensing glucose levels. A white paper detailing the testing and development process has been published by the two companies. The paper explains the process in which the glucose-sensing system is capable of detecting the slightest changes in the glucose levels in the human blood and how it provides a measureable response. In the development process of the sensing system, an exclusive binding assay technique was used to validate the response between the components of the sensing system and the glucose.
The GlucoChip is based on several patents that PositiveID received in 2006 for the Embedded Bio-Sensor System, through patent numbers 382, 125 and 7. The embedded sensor system patent uses radio frequency identification technology (RFID) and a remote transponder. The GlucoChip will be capable of measuring the body’s glucose levels in real-time.
PositiveID also focuses on airborne bio-threat detection technology. MicroFluidic Systems, the company’s wholly-owned subsidiary, is the manufacturer of microfluidic systems and automated instruments used in the preparation of biological assays.
Source: http://www.positiveidcorp.com/